BlinkLab just released an update, announcing that two large US institutions, Cincinnati Children’s Medical Center and Seattle Children’s Research Institute, are joining its FDA 510(k) trial for BlinkLab Dx 1, the AI autism diagnostic platform. This is very positive news, as it shows progress toward that important regulatory green light. Working with these institutions adds credibility, cutting risks around trial execution and improving the odds of FDA clearance. With autism rates rising worldwide and diagnostic bottlenecks begging for quantitative solutions, securing 510(k) status could unlock massive revenue streams through commercialisation, driving share up price and possibly catching the eye of big players in the space. I’m staying bullish on BB1, barring any trial hiccups or regulatory issues.